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Abstract: We aimed to explore the effects of 90Y-DOTATOC and 90Y-DOTATOC plus 177Lu-DOTATOC on survival of pa-
tients with metastasized gastrinoma. Patients with progressive metastasized gastrinoma were treated with repeat-
ed cycles of 90Y-DOTATOC or with cycles alternating between 90Y-DOTATOC and 177Lu-DOTATOC until tumor progression 
or permanent toxicity. Multivariable Cox regression analyses were used to study predictors of survival. A total of 
36 patients were enrolled; 30 patients received 90Y-DOTATOC (median activity per patient 11.8GBq; range: 6.1-
62.2GBq) and 6 patients received 90Y-DOTATOC plus 177Lu-DOTATOC (median activity per patient: 14.8GBq; range: 
7.4-14.8GBq). Response was found in 26 patients (72.2%), including morphological (n=12, 33.3%), biochemical 
(n=14, 38.9%) and/or clinical response (n=6, 16.2%). A total of 21 patients (58.3%) experienced hematotoxicity 
grade 1/2, while 1 patient (2.8%) experienced hematotoxicity grade 3; no grade 4 hematotoxicity occurred. Fur-
thermore, 2 patients (5.6%) developed grade 4 renal toxicity; no grade 5 renal toxicity occurred. Responders had a 
significantly longer median survival from time of enrollment than non-responders (45.1 months, range: 37.1-53.1 
months vs. 12.6 months, range: 11.0-14.2, hazard ratio: 0.12 (0.027-0.52), p=0.005). Additionally, there was a 
trend towards longer median survival with 90Y-DOTATOC plus 177Lu-DOTATOC as compared to 90Y-DOTATOC alone 
(60.2 months, range: 19.8-100.6 months vs. 27.0 months, range: 4.0-50.0, hazard ratio: 0.21 (0.01-3.98), p=0.16). 
Response to 90Y-DOTATOC and 90Y-DOTATOC plus 177Lu-DOTATOC therapy is associated with a longer survival in pa-
tients with metastasized gastrinoma. Both treatment regimens are promising tools for management of progressive 
gastrinoma.
Keywords: Yttrium, lutetium, somatostatin, survival, gastrinoma 
Introduction
Gastrinomas are among the most common 
pancreatic neuroendocrine tumors and surgi-
cal resection is curative for localized disease. 
However, gastrinomas have approximately a 
50% malignant potential and up to 33% of 
patients with gastrinomas have liver metasta-
ses on diagnosis [1]. Therapeutic options for 
patients with metastatic disease are limited, 
and distant metastases are associated with 
increased mortality and an expected 5-year 
survival of 60% [2, 3]. The most common che-
motherapeutics for treatment of metastasized 
gastrinomas are etoposide, cisplatin and doxo-
rubicin, which are associated with significant 
toxicity [4-6], while neither liver transplantation, 
chemo-embolization, nor alpha-interferon ther-
apy have demonstrated significant survival ben-
efit [7, 8].
High expression of somatostatin receptors in 
gastrinoma tissues prompted the use of soma-
tostatin receptor-based radiopeptide imaging 
for detection of gastrinomas with 111In-DTPA-
Octreotide, which demonstrated superior diag-
nostic value compared to morphologic imaging 
[9] and provided the rational to investigate 
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somatostatin-based radiopeptide treatment in 
progressive gastrinoma. 
Somatostatin-based radiopeptide therapy with 
tetraazacyclododecane-tetraacetic acid modi-
fied Tyr-octreotide (DOTATOC) is a valuable ther-
apeutic tool for patients with metastasized 
neuroendocrine cancers [10]. The current prac-
tice in radiopeptide therapy is the use of a sin-
gle radioisotope, typically 90yttrium (90Y) or 
177lutetium (177Lu). 90Y has a long-range, high-
energy β emission that deposits high radiation 
doses in large metastases while 177Lu has a 
short-range, lower-energy β emission that con-
centrates in small metastases. Given their 
complementary characteristics, there is inter-
est in treatment regimens combining the two 
isotopes, and we recently found that DOTATOC 
therapy with both 90Y and 177Lu was more effica-
cious than DOTATOC therapy with 90Y alone in a 
large cohort of patients with neuroendocrine 
tumors [11].
A previous report in 11 gastrinoma patients 
showed that 90Y-DOTATOC or 177Lu-DOTATATE 
resulted in symptomatic improvement and so- 
me degree of tumor response (complete, par-
tial or stabilization) [12]. Here, we report the 
response rate, long-term toxicity profile and 
survival after treatment with 90Y-DOTATOC or 
90Y-DOTATOC plus 177Lu-DOTATOC in 36 patients 
with progressive metastasized gastrinoma.
Methods 
Patients
At the University Hospital Basel, we included 
patients with histologically confirmed gastrino-
ma, metastasized disease, disease progres-
sion within 12 months before study entry and 
visible tumor uptake in the pre-therapeutic 
somatostatin receptor scintigraphy. Patients 
with concurrent anti-tumor treatment other 
than somatostatin treatment were excluded. 
Furthermore, patients with pregnancy, breast-
feeding, urine incontinence, preexisting hema-
tological toxicities grade 3/4, and severe con-
comitant illness including severe psychiatric 
disorders were also excluded. The study was 
designed and carried out in accordance with 
good clinical practice guidelines, Swiss drug 
laws and the Declaration of Helsinki were used 
to design and carry out the study. Approval 
from the local ethics committee for human 
studies (EKBB-Reference-No.: M120/97; www.
ekbb.ch) was obtained and the study was regis-
tered (ClinicalTrials.gov number NCT009- 
78211). All participants or their legal represen-
tatives gave written informed consent.
Treatment
A 5-step process was used to synthesize DOTA-
TOC according to Good Laboratory Practice 
[13]. From October 1997 to February 2001, 
90Y-DOTATOC was the standard treatment. After 
February 2001, combination therapy utilizing 
alternating cycles of 90Y-DOTATOC and 177Lu- 
DOTATOC was available [14]. Due to the uncer-
tain benefit, 177Lu-DOTATOC treatment was per-
formed only in patients living in close proximity 
to Basel.
Radiolabeling was performed with: 3.7GBq/m2 
body surface of 90Y and 0.111GBq of 111Indium 
for intratherapeutic imaging, or with 7.4GBq of 
177Lu. Lyophilized DOTA-TOC kits were incubated 
with the radioisotopes for 30 minutes at 95°C. 
Solid phase extraction and high performance 
liquid chromatography were performed for 
quality control with a minimum required label-
ing yield ≥99.5%.
Amino acid solutions containing lysine and argi-
nine were administered before and after radio-
peptide injection to inhibit tubular re-absorp-
tion [14-16]. Long-acting somatostatin analo- 
gues were withheld for at least 6 weeks and 
short-acting somatostatin analogues were with-
held for at least 3 days prior to radiopeptide 
therapy. Following each cycle, patients were 
hospitalized for 3 days in accordance with 
Swiss regulations for radiation protection.
Based on the results of our pilot study [15], 
repeated treatment cycles were performed 
with a minimum interval of 6 weeks in case of: 
(i) stabilization or decrease in the sum of the 
longest diameters of all pre-therapeutically 
detected tumor lesions, (ii) improvement in at 
least one of the five key symptoms: flush, diar-
rhea, pain, fatigue and involuntary weight-loss 
or (iii) measurable post-therapeutic serum gas-
trin decrease after pre-therapeutic progression 
of serum gastrin. There was no a priori defined 
upper limit of the numbers of treatment cycles. 
Intratherapeutic imaging and image scoring 
were performed as previously described [14, 
17, 18].
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Follow-up
Clinical status and vital signs were monitored 
for 72 hours following each therapeutic applica-
tion with continuous monitoring for evidence of 
toxicity. Following discharge, hematologic para- 
meters were measured at biweekly intervals for 
10 weeks after each cycle or until normaliza-
tion of marker levels. Post-therapeutic morpho-
logical imaging was planned 6-8 weeks after 
each cycle. Measurement of serum gastrin lev-
els was planned 2-8 weeks after treatment.
Further cycles were withheld in case of disease 
progression, permanent toxicity or loss of the 
ability to travel to the treatment center. At this 
point, follow-up was performed to obtain infor-
mation on survival and long-term toxicities until 
the patient’s death. Data were obtained from 
the referring centers with a minimum frequency 
of 2 follow-up visits per year, adapted to the 
patient’s individual requirements. All follow-up 
data were centrally collected and each case 
was reviewed and approved for completeness 
at the study center. Primary physicians and/or 
the patients were directly contacted if addition-
al results were needed.
Acute and long-term adverse events were grad-
ed according to the Common Terminology 
Criteria for Adverse Events version 3.0 (http://
ctep.cancer.gov/forms/CTCAEv3.pdf) of the 
National Cancer Institute. The Modification of 
Diet in Renal Disease (MDRD) formula [19] was 
used to assess kidney function. The guidelines 
of the National Kidney Foundation (www.kid-
Figure 1. Patient Flow.
ney.org) were used to classify renal toxicities, 
where grade 4 and 5 renal toxicity was defined 
as a glomerular filtration rate <30 and <15 mL/
min/1.73 m2, respectively.
Outcomes and statistical analyses
Main outcomes of interest were response to 
treatment, toxicity and survival. Response was 
defined as previously described [14]: (i) Sta- 
bilization or decrease in the sum of the longest 
diameters of all pre-therapeutically detected 
tumor lesions, (ii) improvement in at least one 
of the five key symptoms: flush, diarrhea, pain, 
fatigue and involuntary weight-loss or (iii) mea-
surable post-therapeutic serum gastrin 
decrease after pre-therapeutic progression of 
serum gastrin. Intention-to-treat principles 
were used to define the overall response rate, 
whereby loss of follow-up after treatment was 
regarded as treatment failure.
Pre- and post-therapeutic serum gastrin levels 
were compared using Related Samples Wilco- 
xon Signed Rank Test. Survival was assessed 
from time of first DOTA-TOC treatment to death 
from any cause. Multivariable Cox regression 
was used to study predictors of survival with 
the following pre-specified candidate variables: 
age, response vs. no response, and combined 
treatment with 90Y-DOTATOC plus 177Lu-DOTATOC 
vs. treatment with 90Y-DOTATOC alone. Effect 
estimates were expressed as hazard ratios 
(HR) with 95% confidence intervals (CI). The fre-
quency of hematological toxicity in both treat-
ment groups were compared using binary logis-
tic regression with the pre-specified candidate 
variables used for all survival analyses. 
Sensitivity analyses were performed to assess 
the influence of the cumulative 90Y-DOTATOC 
and 177Lu-DOTATOC activities and the year of 
treatment on all study endpoints. Two-sided p 
values of <0.05 indicate statistical signifi- 
cance.
Results 
Patients
Between October 1996 and February 2010, 45 
patients were screened for eligibility. Of these, 
3 patients (6.6%) were not eligible because of 
absent pre-therapeutic tumor uptake or 
impaired kidney function. Furthermore, 5 eligi-
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132-66000 pg/mL), while the median post-
therapeutic level was 750 pg/mL (range: 58- 
21167 pg/mL, n=14, p=0.001, Figure 3). In 
biochemical non-responders, the median pre-
therapeutic serum gastrin was 399 pg/mL 
(range: 23-43500 pg/mL), while the median 
post-therapeutic level was 1000 pg/mL (range: 
37-526000 pg/mL, n=14, p=0.012, Figure 3).
Survival
After a median follow-up period of 12.3 months 
(range: 1.6-78.8 months), 14 patients (38.9%) 
died and 23 (61.1%) survived. The median sur-
vival was 157.4 months from time of diagnosis 
and 40.1 months from time of enrollment.
Responders had a significantly longer survival 
from time of enrollment (45.1 months, range: 
37.1-53.1 months vs. 12.6 months, range: 
11.0-14.2), in the uni-variable (hazard ratio: 
0.096 (2.4-45.2), p=0.002, Figure 4A) and in 
the multi-variable analysis (hazard ratio: 0.12 
(0.027-0.52), p=0.005, Figure 4B and Table 3). 
Furthermore, there was a trend towards longer 
survival with 90Y-DOTATOC plus 177Lu-DOTATOC 
as compared to 90Y-DOTATOC alone (60.2 
months, range: 19.8-100.6 months vs. 27.0 
ble patients (11.1%) declined participation and 
1 patient (2.2%) was referred for other treat-
ment. The remaining 36 patients (80.0%) were 
recruited (Figure 1). The patients in our study 
came from Europe, North America and Asia.
Treatment
A total of 92 treatment cycles (1-8 cycles per 
patient) were performed, including 81 cycles of 
90Y-DOTATOC (median cumulative activity per 
patient: 11.8GBq; range: 6.1-62.2GBq) and 11 
cycles of 177Lu-DOTATOC (median cumulative 
activity per patient: 14.8GBq; range: 7.4-
14.8GBq). Intratherapeutic scintigraphy revea- 
led visual tumor uptake grade 3 in all 36 
patients (Table 1, Figure 2). 
Response was found in 26 patients (72.2%), 
including morphological (n=12, 33.3%), bio-
chemical (n=14, 38.9%) and/or clinical res- 
ponse (n=6, 16.2%). Overall, the median pre-
therapeutic serum gastrin was 1124 pg/mL 
(range: 23-66000 pg/mL), while the median 
post-therapeutic level was 750 pg/mL (range: 
37-526000 pg/mL, n=36, p=0.26, Figure 3). In 
biochemical responders, the median pre-thera-
peutic serum gastrin was 1838 pg/mL (range: 
Table 1. Baseline Characteristics (n=36)
Characteristic All Patients (n=36) Responders (n=26) Non-responders (n=10)
Gender Women 19 (52.8%) 12 (46.2%) 7 (70.0%)
Men 17 (47.2%) 14 (53.8%) 3 (30.0%)
Age [y] Median 51.9 53.3 50.5
Range 16.2-77.4 16.2-77.4 31.4-75.3
Disease Duration [y] Median 1.9 2.2 1.4
Range 0.1-37.8 0.1-37.8 0.2-27.6
Pretreatment Surgery 20 (55.6%) 15 (57.7%) 5 (50.0%)
Chemotherapy 9 (25.0%) 6 (23.1%) 3 (30.0%)
Radiation 1 (2.8%) 0 (0%) 1 (10.0%)
Extent Single Metastasis 3 (8.3%) 3 (11.5%) 0 (0%)
Liver Metastases 36 (100%) 26 (100%) 10 (100%)
Bone Metastases 5 (13.8%) 1 (3.8%) 4 (40.0)
Creatinine [µmol/L] Median 68 69 59
Range 32-130 38-119 32-130
Tumor Uptake Score 1 0 (0%) 0 (0%) 0 (0%)
Score 2 0 (0%) 0 (0%) 0 (0%)
Score 3 36 (100%) 26 (100%) 10 (100%)
Kidney Uptake Score 0 1 (2.8%) 0 (0%) 1 (10.0%)
Score 1 6 (16.7%) 3 (11.1%) 3 (30.0%)
Score 2 15 (41.7%) 13 (50.0%) 2 (20.0%)
Score 3 13 (36.1%) 10 (38.5%) 3 (30.0%)
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90Y-DOTATOC alone. Two patients (5.6%) devel-
oped grade 4 renal toxicity and no grade 5 renal 
toxicity occurred.
months, range: 4.0-50.0), in the uni-variable 
(hazard ratio: 0.27 (0.06-1.25), p=0.057, Figure 
4C) and in the multi-variable analysis (hazard 
Figure 2. Example of a 51-year old man with metastasized gastrinoma. The intratherapeutic 111In-DOTATOC-scan 
displays focal grade 4 tracer uptake in the liver, right lung, left scapula, spine, ribs, pelvis and left humerus (A). Co-
registered SPECT-CT confirms specific uptake in liver metastases (B). The thoracic lesion is confirmed as a sternal 
metastasis via SPECT-CT (arrow, C). High uptake in viable tumor and absent uptake in necrotic parts of metastases 
is demonstrated (arrow, D). The serum gastrin did not drop after the first four treatment cycles; however, at later 
cycles a significant drop in serum gastrin levels occurred.
Figure 3. Pre- and post-therapeutic serum gastrin levels in all patients (A), bio-
chemical responders (B) and biochemical non-responders (C).
ratio: 0.21 (0.01-3.98), 
p=0.16, Figure 4D and Ta- 
ble 3).
Toxicities
In total, 21 patients (58.3%) 
experienced hematotoxicity 
grade 1/2, while 1 patient 
(2.8%) experienced hema-
totoxicity grade 3; no grade 
4 hematotoxicity occurred 
(Table 2). There was no sig-
nificant difference in the 
frequencies of grade 1/2 
hematotoxicities (p=0.23) 
and no difference in the fre-
quencies of grade 3/4 
hematotoxicities (p=0.99) 
with 90Y-DOTATOC plus 177Lu- 
DOTATOC as compared to 
DOTATOC in gastrinoma
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Discussion
Given the limited therapeutic options available 
to patients with metastasized gastrinoma, th- 
ere is a need to establish well-tolerated agents 
that prolong survival. Traditional agents used in 
the treatment of metastasized gastrinoma are 
known to cause frequent serious side effects 
without proven prolonged survival [5-7, 20]. 
More promising results have been seen with 
targeted therapies, which exploit aberrant mole- 
cular pathways known to be overexpressed or 
overactive in gastrinomas. The somatostatin 
analog octreotide LAR has been shown to 
induce disease control in about 50% of patients 
with metastasized gastrinoma [21], with similar 
results seen for the protein kinase inhibitors 
Everolimus and Sunitinib [22, 23], however long 
term survival data is lacking for these agents. 
In our cohort, 72% of patients showed a res- 
ponse to DOTATOC therapy that was associated 
with longer overall survival, indicating that 
radiopeptide therapy with somatostatin based 
analogues may be an effective means of treat-
ment for patients with progressive metasta-
sized gastrinoma. 
The clinical paradigm of gastrinoma, known as 
Zollinger-Ellison Syndrome, is secondary to gas-
tric acid hypersecretion and causes serious 
Figure 4. Survival of responders vs. non-responders in the uni-variable (A) and multivariable analysis (B). Survival of 
patients treated with 90Y-DOTATOC vs. patients treated with 90Y-DOTATOC plus 177Lu-DOTATOC in the uni-variable (C) 
and multivariable analysis (D).
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peptic ulcers, gastro-esophageal reflux and 
diarrhea, significantly contributing to the mor-
bidity of patients with gastrinoma [24]. About 
one third of patients in our cohort demonstrat-
ed a biochemical response to DOTATOC therapy 
with a significant reduction in post-therapeutic 
gastrin levels. As demonstrated by the patient 
example, significant reduction in gastrin levels 
may occur later in the course of therapy even 
with initial nonresponse. While clinical response 
can often be induced with radiopeptide treat-
ment, protein kinase inhibitors rarely have this 
effect and instead can result in a multitude of 
other side effects that contribute to patient 
morbidity (e.g. rash, stomatitis, diarrhea, arthr- 
algia). 
DOTATOC therapy was generally well tolerated 
in our cohort of patient. Hematotoxicity is a 
well-known toxicity associated with radiopep-
tide therapy that is thought to occur due to irra-
diation from 90Y-DOTATOC circulating through 
the body or binding to somatostatin receptors 
on bone marrow cells [25], or due to the small 
fraction of free 90Y that is administered during 
treatment cycles that integrates into the bone 
matrix [26]. Low-grade hematotoxicity was rela-
tively common in our cohort, with approximate-
ly 60% of patients experiencing grade 1 or 2 
hematotoxicity. Overall, there was no significant 
difference in the frequencies of hematotoxici-
ties with combination therapy as compared to 
90Y-DOTATOC alone. Renal toxicity, the main 
adverse effect after radiopeptide therapy, 
occurred at rates similar to or lower than those 
reported for most radiopeptide trials using 90Y 
or 177Lu [16, 27-29]. 
The trend toward longer survival with combined 
90Y-DOTATOC plus 177Lu-DOTATOC therapy com-
pared to 90Y-DOTATOC alone in patients with 
metastasized gastrinoma is consistent with 
findings we previously reported in patients with 
neuroendocrine tumors [11]. The improved sur-
vival associated with combination therapy with 
long-range, high-energy 90Y and short-range, 
lower-energy 177Lu is thought to be due to spa-
tial differences in the deposition of energy [30]. 
To our knowledge, no randomized trials have 
been performed on the superiority of one of 
these radionuclides in radiopeptide therapy, or 
on identifying in which cases these radionu-
clides may be preferred (i.e. tumor location, 
tumor perfusion, large tumor size). Such work 
would be helpful in defining which patient 
cohorts would most benefit from 90Y- and 
177Lu-based radiopeptide therapy.
Previously, we have shown that qualitative anal-
ysis of scintigraphic uptake of the radiopeptide 
is able to predict survival in patients with neu-
roendocrine tumors undergoing 90Y-DOTATOC 
treatment [14]. These findings suggest that a 
quantitative approach using 68Ga-DOTATOC-
Table 2. Hematological Toxicities (n=36)
Total Grade 1 Grade 2 Grade 3 Grade 4
90Y-DOTATOC (n=30)
    Leukopenia 9 (30.0%) 2 (6.7%) 7 (23.3%) 0 (0%) 0 (0%)
    Anemia 20 (66.7%) 16 (53.3%) 3 (10%) 1 (3.3%) 0 (0%)
    Thrombocytopenia 7 (23.3%) 5 (16.7%) 2 (6.7%) 0 (0%) 0 (0%)
90Y-DOTATOC plus 177Lu-DOTATOC (n=6)
    Leukopenia 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
    Anemia 1 (16.7%) 0 (0%) 1 (16.7%) 0 (0%) 0 (0%)
    Thrombocytopenia 1 (16.7%) 1 (16.7%) 0 (0%) 0 (0%) 0 (0%)
All toxicities are scored according to the NCI criteria.
Table 3. Hazard Ratios for Overall Survival (n=36)
Covariate Hazard Ratio (95% CI)* P Value
Age (per year) 1.01 (0.97-1.06) 0.54
Response (vs. no response) 0.12 (0.027-0.52) 0.005
90Y-DOTATOC plus 177Lu-DOTATOC (vs. 90Y-DOTATOC) 0.27 (0.043-1.70) 0.16
*Estimates for each co-variable have been adjusted for the cumulative DOTATOC activity as well as for all other co-variables 
listed.
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PET could be used in the future to even more 
precisely predict radiotherapeutic outcome. In 
the present study, however, all tumors demon-
strated high tracer uptake, precluding any cor-
relation analysis on uptake and survival. 
The present study has strengths and limita-
tions. To our knowledge, this is the largest study 
to date showing a treatment-related survival 
benefit in patients with metastasized gastrino-
ma. The relatively long patient follow-up was 
sufficient to obtain the significant results 
described above. The patients in our study 
came from Europe, North America and Asia, 
resulting in a diverse cohort that is more widely 
representative of a global population rather 
than that limited to a single country. Given that 
there is currently no accepted standard regi-
men for DOTATOC therapy in the Nuclear 
Medicine community, the administration of 
treatment at a single center ensured homoge-
neity of intervention. However, because of fac-
tors such as year of enrollment, proximity to the 
University Hospital Basal and baseline renal 
function, patients were not randomly stratified 
to the different treatment regimens. 
Additionally, our patients came from a variety of 
different referral centers at which initial staging 
and follow up was performed. This sometimes 
resulted in non-uniform ordering of imaging 
and laboratory tests. Finally, this study was 
conducted over a long time period given the 
relative rarity of metastasized gastrinoma. Our 
current findings warrant prospective evaluation 
in a randomized trial. 
In conclusion, the longer survival associated 
with response to DOTATOC radiotherapy makes 
it a promising treatment option for patients 
with metastasized gastrinoma.
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